Poor
Mostly Aligned
Patient Risk:
Moderate
Summary
Only two label-aligned claims were evaluated (identity and emergency opioid overdose reversal indication). Several other claims concern coupons/patient assistance, which are not addressed in the provided FDA label excerpts, making them unsupported by the provided prescribing information. No label content supports the financial/coverage statements.
Category Scores
Accurate Statements
Opvee is nalmefene.
Label identifies OPVEE as nalmefene (provided evidence includes active ingredient nalmefene).
Nalmefene is used as an emergency treatment for opioid overdose reversal.
1 INDICATIONS AND USAGE: indicated for emergency treatment of known or suspected overdose induced by natural or synthetic opioids; mechanism described as opioid receptor antagonist reversing opioid effects.
Unsupported Statements
Coupons and patient assistance can vary by country, pharmacy, and insurance plan.
No coupon/patient assistance/coverage content is present in the provided prescribing information excerpts.
Copay coupons cannot be used when insurance already covers the medication in certain ways.
No coupon usage restrictions or payer-coverage rules are described in the provided prescribing information excerpts.
Copay coupons may only reduce out-of-pocket cost to a limit.
No information about copay coupon limits is present in the provided prescribing information excerpts.
Whether a copay coupon can be used depends on insurance type (commercial vs. Medicare/Medicaid).
No statements about insurance-type eligibility for coupons are present in the provided prescribing information excerpts.
Whether a copay coupon can be used depends on whether the program is a copay card vs. a patient assistance program.
No distinctions between copay card vs patient assistance program are described in the provided prescribing information excerpts.
Whether a copay coupon can be used depends on the terms on the specific coupon.
No statements about dependence on coupon terms are present in the provided prescribing information excerpts.
Contradictions
Important Omissions
Labeled dosage and administration instructions (e.g., initial dose and repeat dosing intervals of 2–5 minutes with a new device; do not prime/test/reuse; seek emergency medical assistance and keep under surveillance) were not addressed by the AI claims listed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the emergency overdose reversal indication statement is supported, the other claims are unsupported by the provided label and may distract from label-required emergency administration/monitoring instructions (which were omitted).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Coupon/patient assistance and payer-eligibility statements are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to information present in the FDA label excerpts (indication and labeled emergency dosing/administration instructions). Remove or qualify coupon/patient assistance statements as not covered by the prescribing information.